Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05365802
EARLY_PHASE1

FAPI PET for Lung Fibrosis

Sponsor: University of California, Los Angeles

View on ClinicalTrials.gov

Summary

This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview. Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan and one High Resolution CT of the lungs. The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.

Official title: PET Study of 68Ga-FAPi-46 in Patients With Interstitial Lung Disease: an Exploratory Biodistribution Study With Histopathology Validation.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2021-11-16

Completion Date

2026-12

Last Updated

2025-07-03

Healthy Volunteers

No

Interventions

DRUG

68Ga-FAPi-46

Radiopharmaceutical will be administered via IV

PROCEDURE

Computed Tomography

As part of PET/CT scan

PROCEDURE

Positron Emission Tomography

As part of PET/CT scan

PROCEDURE

High Resolution Computed Tomography

Will be conducted immediately after FAPI PET/CT

Locations (1)

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States